Neuroprotective strategies for neonatal hypoxic-ischemic brain damage: Current status and challenges
Qing You,Xiao-Bing Lan,Ning Liu,Juan Du,Lin Ma,Jia-Mei Yang,Jian-Guo Niu,Xiao-Dong Peng,Gui-Lin Jin,Jian-Qiang Yu,Xiao-bing Lan,Jia-mei Yang,Jian-guo Niu,Xiao-dong Peng,Gui-lin Jin,Jian-qiang Yu
DOI: https://doi.org/10.1016/j.ejphar.2023.176003
IF: 5.195
2023-08-27
European Journal of Pharmacology
Abstract:Neonatal hypoxic-ischemic brain damage (HIBD) is a prominent contributor to both immediate mortality and long-term impairment in newborns. The elusive nature of the underlying mechanisms responsible for neonatal HIBD presents a significant obstacle in the effective clinical application of numerous pharmaceutical interventions. This comprehensive review aims to concentrate on the potential neuroprotective agents that have demonstrated efficacy in addressing various pathogenic factors associated with neonatal HIBD, encompassing oxidative stress, calcium overload, mitochondrial dysfunction, endoplasmic reticulum stress, inflammatory response, and apoptosis. In this review, we conducted an analysis of the precise molecular pathways by which these drugs elicit neuroprotective effects in animal models of neonatal hypoxic-ischemic brain injury (HIBD). Our objective was to provide a comprehensive overview of potential neuroprotective agents for the treatment of neonatal HIBD in animal experiments, with the ultimate goal of enhancing the feasibility of clinical translation and establishing a solid theoretical foundation for the clinical management of neonatal HIBD.
pharmacology & pharmacy